DiaMedica Therapeutics Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 5.15 million compared to USD 5.27 million a year ago. Basic loss per share from continuing operations was USD 0.14 compared to USD 0.2 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.05 USD | +3.04% |
|
+33.77% | +7.39% |
06-27 | Transcript : DiaMedica Therapeutics Inc. - Special Call | |
06-26 | DiaMedica Therapeutics Inc. Plans to Expand Its Clinical Trials into Preeclampsia | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.39% | 112M | |
+16.13% | 122B | |
+19.65% | 115B | |
+21.22% | 26.64B | |
-23.84% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-19.28% | 15.49B | |
+63.81% | 14.83B | |
+1.94% | 13.67B |
- Stock Market
- Equities
- DMAC Stock
- News DiaMedica Therapeutics Inc.
- DiaMedica Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024